FDA cleared Earflo for children 2 years and older with negative middle ear pressure, expanding at-home autoinflation options.
The FDA has cleared, and the US market now has access to Earflo, an at-home device intended for children aged 2 years and older with negative middle ear pressure, according to an April 29 company announcement.1 The clearance is clinically relevant because otitis media with effusion (OME) and eustachian tube dysfunction are common in early childhood, and management often consists of observation before referral for tympanostomy tubes.2,3
“We built Earflo because we know how exhausting and heartbreaking it is to watch a little one struggle with ear pain, hearing issues, and disrupted learning,” said Intan Oldakowska, PhD, CEO and cofounder of Earflo, in the company release. She described the device as a “science-backed tool” for home use before surgery is considered.
According to the press release, the device delivers a controlled puff of air through the nose during swallowing to help open the eustachian tube, equalize middle ear pressure, and reduce fluid buildup associated with OME.^1 The system is paired with a mobile application intended to guide treatment sessions and track adherence. The company said the product is cleared for children as young as 2 years. The announcement did not specify the FDA pathway, clearance date, or product code, and those details were not included in the source material.
The company also cited peer-reviewed clinical research supporting the device, reporting that 86% of children had immediate improvement in middle ear pressure, 86% had significantly improved hearing after 4 weeks, and 89% avoided surgery. However, the press release did not name the study, provide sample size, comparator details, confidence intervals, or adverse-event rates, limiting interpretation of the magnitude and durability of benefit.
That uncertainty matters because most OME resolves spontaneously. The American Academy of Otolaryngology-Head and Neck Surgery Foundation guideline recommends watchful waiting for 3 months in children who are not at risk for speech, language, or learning problems, reflecting the self-limited nature of many cases.3 Tympanostomy tubes remain standard treatment for selected children with persistent effusion and hearing difficulty or other symptoms, but clinicians and families often seek options during the observation period.2,3
Autoinflation is not a new concept in middle ear disease. Devices that increase nasopharyngeal pressure during swallowing or forced exhalation have been studied as a noninvasive approach to improve middle ear ventilation.4 Evidence has suggested short-term improvements in tympanometry and, in some studies, hearing-related outcomes, although uptake in routine practice has varied because of age-related cooperation, adherence, and limited familiarity in US settings.4 Earflo appears to enter that therapeutic space with a design tailored for younger children and app-supported use, but the comparative advantage over existing autoinflation approaches is not yet clear from the available information.
In the same release, Peter Santa Maria, MD, chief medical officer of Earflo and professor and division chief of otology and neurotology at the University of Pittsburgh, said, “For the first time, parents have something they can actually do, and the clinical data shows it works.”^1 That interpretation should be weighed against the limited publicly available details on trial methods and safety. Without a full report, clinicians cannot assess whether outcomes were based on tympanometry, audiometry, symptom scores, or surgical referral patterns, nor can they determine which patients are most likely to benefit.
If subsequent peer-reviewed publication and FDA documentation confirm favorable efficacy and usability, the device could offer a practical adjunct during watchful waiting, particularly for children with persistent negative pressure or effusion who can reliably participate in therapy. For now, the main unanswered questions are comparative effectiveness, adherence outside trial settings, adverse events such as discomfort or epistaxis, and whether use reduces tympanostomy rates in broader practice.
